Literature DB >> 16843438

Telomerase reverse transcriptase regulates the expression of a key cell cycle regulator, cyclin D1.

Shankar Jagadeesh1, Partha P Banerjee.   

Abstract

Cells require a mechanism to maintain telomere stability in order to overcome replicative senescence and telomerase catalyzes the synthesis and extension of telomeric DNA, therefore, be a rate-limiting step in cellular immortality and oncogenesis. However, some studies have raised questions about whether the stabilization of chromosome ends entirely explains the ability of telomerase to promote tumorigenesis. To elucidate non-canonical functions of human telomerase reverse transcriptase (hTERT), we used loss-of-function and gain-of-function studies. We demonstrated that hTERT shRNA down-regulated and hTERT overexpression up-regulated the expression and transcriptional activity of a key cell cycle regulator, cyclin D1, in human prostate epithelial cell lines, DU-145 and BPH-1. Based on these observations, we propose that in addition to its well-defined function in telomere length regulation, hTERT has a novel role in the modulation of cyclin D1 expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16843438     DOI: 10.1016/j.bbrc.2006.06.172

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Downregulation of telomerase activity by diclofenac and curcumin is associated with cell cycle arrest and induction of apoptosis in colon cancer.

Authors:  Chandan Rana; Honit Piplani; Vivek Vaish; Bimla Nehru; S N Sanyal
Journal:  Tumour Biol       Date:  2015-03-06

2.  Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells.

Authors:  Crystal N Marconett; Shyam N Sundar; Min Tseng; Antony S Tin; Kalvin Q Tran; Kelly M Mahuron; Leonard F Bjeldanes; Gary L Firestone
Journal:  Carcinogenesis       Date:  2011-06-21       Impact factor: 4.944

3.  The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin.

Authors:  Amal Shervington; Vidya Pawar; Sharad Menon; Dipti Thakkar; Rahima Patel
Journal:  Mol Biol Rep       Date:  2008-06-26       Impact factor: 2.316

4.  Keeping an eye on retinoblastoma control of human embryonic stem cells.

Authors:  Jamie F Conklin; Julien Sage
Journal:  J Cell Biochem       Date:  2009-12-01       Impact factor: 4.429

5.  Replication licensing promotes cyclin D1 expression and G1 progression in untransformed human cells.

Authors:  Peijun Liu; Damien M Slater; Marc Lenburg; Kathleen Nevis; Jeanette Gowen Cook; Cyrus Vaziri
Journal:  Cell Cycle       Date:  2009-01-01       Impact factor: 4.534

Review 6.  Telomeres and telomerase in prostate cancer development and therapy.

Authors:  Mindy Kim Graham; Alan Meeker
Journal:  Nat Rev Urol       Date:  2017-07-04       Impact factor: 14.432

Review 7.  Telomerase reverse transcriptase in the regulation of gene expression.

Authors:  Junzhi Zhou; Deqiang Ding; Miao Wang; Yu-Sheng Cong
Journal:  BMB Rep       Date:  2014-01       Impact factor: 4.778

Review 8.  Telomere and Telomerase Therapeutics in Cancer.

Authors:  Yucheng Xu; Amir Goldkorn
Journal:  Genes (Basel)       Date:  2016-05-26       Impact factor: 4.096

9.  Metabolic Reprogramming Drives Pituitary Tumor Growth through Epigenetic Regulation of TERT.

Authors:  Hiromi Onizuka; Kenta Masui; Kosaku Amano; Takakazu Kawamata; Tomoko Yamamoto; Yoji Nagashima; Noriyuki Shibata
Journal:  Acta Histochem Cytochem       Date:  2021-06-23       Impact factor: 1.938

10.  A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis.

Authors:  Shintaro Imamura; Junzo Uchiyama; Eriko Koshimizu; Jun-Ichi Hanai; Christina Raftopoulou; Ryan D Murphey; Peter E Bayliss; Yoichi Imai; Caroline Erter Burns; Kenkichi Masutomi; Sarantis Gagos; Leonard I Zon; Thomas M Roberts; Shuji Kishi
Journal:  PLoS One       Date:  2008-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.